HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results

Go back to HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results

HealthEquity, Inc (HQY) PT Raised to $97 at BofA Securities

March 20, 2024 4:41 AM EDT

BofA Securities analyst Allen Lutz raised the price target on HealthEquity, Inc (NASDAQ: HQY) to $97.00 (from $93.00) while maintaining a Buy rating.

The analyst comments "HealthEquity reported a strong quarter, with strong expense management in Technology & Development the largest upside driver versus our model. FY25 revenue and EBITDA guidance was in line... More

HealthEquity, Inc (HQY) PT Raised to $110 at BTIG

March 20, 2024 4:11 AM EDT

BTIG analyst David Larsen raised the price target on HealthEquity, Inc (NASDAQ: HQY) to $110.00 (from $100.00) while maintaining a Buy rating.

The analyst comments "On Tuesday, 3/19/24 AMC, HQY reported excellent F4Q:24 results. Total revenue of $262.4M +12% y/y exceeded BTIG / consensus estimates of $260.7M / $258.7M and adjusted EBITDA of $98.8M +34% y/y also exceeded BTIG / consensus estimates of $98M / $91.5M. HQY re-affirmed revenue guidance for... More

HealthEquity (HQY) Tops Q4 EPS by 7c, Offers Guidance

March 19, 2024 4:03 PM EDT

HealthEquity (NASDAQ: HQY) reported Q4 EPS of $0.63, $0.07 better than the analyst estimate of $0.56. Revenue for the quarter came in at $262.4 million versus the consensus estimate of $258.31 million.

GUIDANCE:

HealthEquity sees FY2025 EPS of $2.79-$2.96, versus the consensus of $2.84. HealthEquity sees... More